CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Lorazepam 1 mg IM +3 moredrug
Likely dose
Lorazepam 1 mg IMfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01877642
NCT01877642Phase 4Completed

ADASUVE®-Lorazepam Drug-Drug Interaction Study

Alexza Pharmaceuticals, Inc.·interventional·Posted Jun 14, 2013·Updated Dec 13, 2017

In Brief

A Phase 4 clinical trial evaluating Lorazepam 1 mg IM, Inhaled loxapine 10 mg, and 2 other interventions for Healthy Volunteers. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This study will compare the safety and effects over time for giving both ADASUVE and lorazepam (intramuscular) compared to that of each agent given alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 14, 2013
Enrollment StartJun 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.0 years ago

Interventions

Lorazepam 1 mg IMdrug

Lorazepam 1 mg intramuscular

Inhaled loxapine 10 mgdrug

Inhaled Staccato loxapine 10 mg

Inhaled Placebodrug

Inhaler with no drug in it to mimic the ADASUVE inhaler

Placebo IMdrug

intramuscular placebo to mimic lorazepam 1 mg IM